CompletedNot Applicable

Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.

Egypt50 participantsStarted 2025-08-01

Plain-language summary

The aim of the study is to 1. Evaluate the preventive value of Lactoferrin on VAP among ventilated neonates. 2. Evaluate the Primary outcome of Lactoferrin on: Sepsis, Feeding intolerance, Vomiting, Constipation or diarrhea 3. Evaluate the effect of Lactoferrin in critically ventilated neonates on: Incidence of VAP Duration of mechanical ventilation Duration of hospital stay

Who can participate

Age range0 Days – 90 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Preterm neonates requiring mechanical ventilation. Gestational age: (GA 28-36 weeks). Expected need for mechanical ventilation for ≥ (48hours) Exclusion Criteria: Congenital anomalies of the lung or airway. Major congenital heart disease. Proven early-onset sepsis at enrollment. Severe perinatal asphyxia (e.g., Apgar \< 3 at 5 minutes or seizures). Known contraindication or allergy to lactoferrin. Severe gastrointestinal pathology (e.g., NEC stage II or higher). Any condition deemed by the clinical team to interfere with study participation.

What they're measuring

Prevention of VAP

Timeframe: From enrollment until day 28 of life or NICU discharge, whichever occurs first.

Prevention of VAP

Timeframe: during NICU stay

Trial details

NCT IDNCT07255742

SponsorDalia Mohamed Salah

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-01

View on ClinicalTrials.gov More Ventilator Associated Pneumonia trials